A Semi-Public Utility?
Executive SummaryIn most industries, creating strong demand for products is the key to proprietary value--and the more demand, the greater the value. But in the case of both drug and Internet companies this past year, the very thing that should have created enormous value--the potential for extremely wide-scale adoption of their products--instead fostered push back when adoption threatened to become too widespread because it was too valuable for any one company to have on an exclusive basis. The tremendous importance that both pharmaceuticals and the Internet, for different reasons, have assumed in people's lives has turned what should be a proprietary asset into something closer to a semi-public utility.
You may also be interested in...
Roche receives initial knockback for lymphoma treatment which could rival CAR-T therapies.
Parliamentary debate next week on the post-Brexit regulatory adjustments ahead for the UK medical devices industry will coincide with the opening of post-Brexit EU trade talks by the UK government. After a period of nervous calm, Brexit will be back with a bang.